- Home
- SJT vs BWAY Comparison
SJT vs BWAY Comparison
Compare SJT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- BWAY
- Stock Information
- Founded
- SJT 1980
- BWAY 2003
- Country
- SJT United States
- BWAY Israel
- Employees
- SJT N/A
- BWAY N/A
- Industry
- SJT Oil & Gas Production
- BWAY Medical/Dental Instruments
- Sector
- SJT Energy
- BWAY Health Care
- Exchange
- SJT Nasdaq
- BWAY Nasdaq
- Market Cap
- SJT 212.1M
- BWAY 177.4M
- IPO Year
- SJT N/A
- BWAY 2019
- Fundamental
- Price
- SJT $4.44
- BWAY $10.23
- Analyst Decision
- SJT
- BWAY Strong Buy
- Analyst Count
- SJT 0
- BWAY 3
- Target Price
- SJT N/A
- BWAY $13.17
- AVG Volume (30 Days)
- SJT 317.1K
- BWAY 49.6K
- Earning Date
- SJT 11-14-2024
- BWAY 03-05-2025
- Dividend Yield
- SJT 2.50%
- BWAY N/A
- EPS Growth
- SJT N/A
- BWAY N/A
- EPS
- SJT 0.19
- BWAY 0.04
- Revenue
- SJT $11,031,594.00
- BWAY $38,631,000.00
- Revenue This Year
- SJT N/A
- BWAY $388.82
- Revenue Next Year
- SJT N/A
- BWAY $18.70
- P/E Ratio
- SJT $24.13
- BWAY $129.57
- Revenue Growth
- SJT N/A
- BWAY 34.19
- 52 Week Low
- SJT $3.21
- BWAY $4.61
- 52 Week High
- SJT $5.81
- BWAY $10.98
- Technical
- Relative Strength Index (RSI)
- SJT 58.04
- BWAY 61.17
- Support Level
- SJT $4.36
- BWAY $9.18
- Resistance Level
- SJT $4.81
- BWAY $9.75
- Average True Range (ATR)
- SJT 0.23
- BWAY 0.34
- MACD
- SJT 0.06
- BWAY 0.11
- Stochastic Oscillator
- SJT 67.83
- BWAY 88.67
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.